Home
About
FAQ
History (21)
Interleukin-1
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
Anomie
Filipin
Risk-adapted approaches to therapy for high-risk acute promyelocytic leukemia.
See All 21 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Risk-adapted approaches to therapy for high-risk acute promyelocytic leukemia.
Ranganathan A, Powell BL. Risk-adapted approaches to therapy for high-risk acute promyelocytic leukemia. Clin Lymphoma Myeloma Leuk. 2010 Oct; 10 Suppl 3:S135-8.
View in:
PubMed
subject areas
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Clinical Trials as Topic
Humans
Leukemia, Promyelocytic, Acute
Recurrence
Risk Factors
Survival Analysis
Time Factors
Treatment Outcome
authors with profiles
Bayard L. Powell MD